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Abstract 
AIM: The study was aimed at researching the specific wound healing activity of the drug with a comprehensive 
therapeutic effect based on derivatives of glucosamine and acrylic polymers to treat the infected wounds of 
various origins on a model of a planar infected wound. 
METHODS: The model of septic wounds in rats as per the method of P.I. Tolstykh was used during the study of 
the specific activity of the drug with a comprehensive therapeutic effect based on derivatives of glucosamine and 
acrylic polymers for the treatment of infected wounds. The infection was performed with the S. aureus and E. coli 
strains. The study lasted 18 days, and during this period no full scarring occurred. The wound diameter was 
chosen as the effectiveness criterion. The planimetric method was used to assess the course of the wound 
process in experimental animals. 
RESULTS: The obtained data prove the specific action of the drug with a comprehensive therapeutic action 
based on derivatives of glucosamine and acrylic polymers to treat the infected wounds of various origins. The 
study has shown that bacterially infected wounds healed worse than noninfected ones. Both types of wounds — 
infected and uninfected ones — healed faster when applying the test drug or Levomekol ointment.  
CONCLUSION: On the model of a planar infected wound, the developed drug with a comprehensive therapeutic 
action has shown better wound healing effect compared with the Levomekol reference drug. 
 
 
 
 
 
 
 
 
Introduction 
 
The drug with a comprehensive therapeutic 
action based on derivatives of glucosamine and 
acrylic polymers to treat the infected wounds of 
various origin is a translucent gel based on 
hydroxypropyl cellulose and polyacrylamide, with the 
inclusion of chitosan, hemopexin, miramistin and 
lidocaine hydrochloride as pharmaceutical agents 
(Brkich, Pyatigorskaya, 2017) [1].  
The drug for the treatment of infected wounds 
has four types of pharmacological effects, namely 
necrolytic, antimicrobial, wound healing and 
anaesthetic ones.  
The necrolytic effect is ensured by 
hemopexin, providing a lysing effect on septic 
substrates and cleansing the wound surface from 
purple-necrotic masses. When applied to tissue, 
hemopexin splits fibrinous formations and necrotic 
tissue structures, and blood clots. It also thins exudate 
and vicious secret. Himopsin restores microcirculation 
in the wound walls, improves metabolic processes, 
which is clinically manifested by a decrease in local 
inflammation.  
Chitosan is a carrier of the enzyme complex. 
It provides a prolonged therapeutic effect of himopsin 
and has a wound healing effect.  
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The antimicrobial action is ensured by the 
presence of Miramistin antiseptic (benzyl dimethyl [3-
(myristoylamino) propyl] ammonium chloride 
monohydrate). The compound has a pronounced 
bactericidal action against aerobic and anaerobic 
bacteria, gram-positive (Staphylococcus, 
Streptococcus, Bacillus subtilis, Bacillus anthracoides) 
and gram-negative organisms (Shigella, 
Pseudomonas aeruginosa, Escherichia coli, 
Salmonella), as well as against hospital strains 
multiresistant to antibiotics. Miramistin provides 
antimicrobial and fungicidal action, enhances the 
functional activity of immune cells, while stimulating 
local (nonspecific) immunity, accelerates the wound 
healing process, reduces the resistance of pathogenic 
microorganisms to antibiotic therapy, and activates 
protective reactions at the application site through the 
activation of the absorbing and digestive functions of 
phagocytes.  
The analgesic effect is due to the presence of 
lidocaine anaesthetic, which has a local anaesthetic 
effect, blocks potential-dependent sodium channels, 
thereby preventing the generation of impulses in the 
endings of sensory nerves and conduction of impulses 
along nerve fibres. The anaesthetic action of lidocaine 
is 2 – 6 times stronger than that of novocaine and 
procaine. When applied locally, it dilates blood 
vessels and has no irritating local action.  
The study was aimed at researching the 
specific wound healing activity of the drug with a 
comprehensive therapeutic effect on a model of a 
planar infected wound. 
 
 
Material and Methods 
 
The drug is a gel for external use, containing 
per 100 g: himopsin – 0.2 g, miramistin – 0.05 g, 
chitosan – 2 g, lidocaine – 0.1 g, polyacrylamide – 0.1 
g, hydroxypropylmethylcellulose – 2 g, glycerin – 5.0 
g, and water – up to 100 g. 
A group of 45 male rats of the Wistar line, 
weighing 200 – 240 g, (Stolbovaya branch of the 
FSBUN NCBMT FMBA of Russia) were used in the 
study. 
The bacterial strains of the American Type 
Culture Collection (ATCC) obtained from the ACM 
(All-Russian Collection of Microorganisms) of Moscow 
were used in the experiment. The species 
composition was represented by the following 
microorganisms: Escherichia coli (АТСС 25922); 
Staphylococcus aureus (ATCC 6538-R). 
The antibacterial effect of the studied objects 
was studied by the "wells" method. Bacteria were 
cultivated in L-broth at 37°C for 20 hours. Then, the 
number of cells per 1 ml of the initial suspension was 
determined using the Koch method. For further 
research, dilutions were used, providing the medium 
contamination on a Petri dish of 10
4
 and 10
6
 CFU/ml, 
which corresponded to the initial dissemination of the 
wound.  
From the obtained dilutions, previously 
thoroughly mixed, bacteria were sown on the surface 
of the agar plate in a Petri dish with a sterile pipette in 
the amount of 0.1 ml. The volume of the applied 
suspension was distributed over the surface of the 
medium with a sterile spatula.  
The septic wound was modelled for the 
animals under anaesthesia under sterile conditions as 
per the P.I. Tolstykh method (1976) [2]. For this 
purpose, the skin with subcutaneous tissue 25 mm in 
diameter was dissected into on the antiseptic-treated 
back section shaved from wool. A gauze plug 
containing 1.2 x 10
9
 microbial bodies of the S. aureus 
daily culture or 2.6 x 10
9
 E. coli was introduced into 
the resulting wound, and the wound was sutured. On 
the following day (24 hours), after modelling, the 
abscess with all the characteristic signs of 
inflammation was formed in all animals. After the 
stitches’ removal, the upper skin flap was removed, 
the gauze plug was removed, and the purulence was 
evacuated. The area of the original wound was 
determined by applying a contour to a transparent 
film. 
Treatment of the wound with the test drug or 
Levomekol reference product was started 24 hours 
after the septic wound modelling. The drugs were 
applied for 18 days. During the treatment, the 
diameter of the wound was measured every three 
days. Planimetric method was used to assess the 
course of the wound process in experimental animals. 
 
 
Results 
 
The animals were divided into groups, in 
accordance with the doses of the injected substance 
(Table 1). 
Table 1: Groups of animals 
No. Infection type Drug Number of animals Drug dose, g/kg 
1.  S. aureus Gel, 0.2 g/200 g 3♂ 1 
2.  E. coli 3♂ 
3.  S. aureus Gel, 0.1 g/200 g 3♂ 5 
4.  E. coli 3♂ 
5.  S. aureus Levomekol, 0.2 g/200 g 3♂ 1 
6.  E. coli 3♂ 
7.  S. aureus Levomekol, 1 g/200 g 3♂ 5 
8.  E. coli 3♂ 
9.  S. aureus Without drug 3♂ - 
10.  E. coli 3♂ 
11.  Without infection Gel, 0.2 g/200 g 3♂ 1 
12.  Gel, 1 g/200 g 3♂ 5 
13.  Levomekol, 0.2 g/200 g 3♂ 1 
14.  Levomekol, 1 g/200 g 3♂ 5 g/kg 
15.  Without drug 3♂ - 
 
After modelling a septic wound, rats in all 
groups of the test drug, the Levomekol reference 
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drug, and the wounds without drugs were sluggish in 
the first two days of the study. The wound at the 
beginning of the study is presented in Figure 1. 
 
Figure 1: Wound at the beginning of the study 
 
The wound diameter during the treatment was 
measured planimetrically every three days. The data 
are shown in Table 2. 
Table 2: The result of measuring the size of the wound during 
the study 
No. Infection 
type 
Drug Wound size, cm 
Days of infection 
1 3 6 9 12 15 18 
1.  S. aureus Test drug, 0.2 g/200 g 2.7 2.5 2.1 2.0 1.2 1.0 0.5 
2.6 2.5 2.0 1.8 1.0 0.7 0.3 
2.5 2.3 2.1 1.9 1.4 1.1 0.7 
Average: 2.6 2.4 2.06 1.9 1.2 0.93 0.5 
2.  E. coli Test drug, 0.2 g/200 g 2.3 2.3 2.0 1.9 1.3 1.1 0.6 
2.5 2.5 2.3 2.2 1.2 1.0 0.5 
2.3 2.3 2.0 1.8 0.9 0.7 0.3 
Average: 2.36 2.36 2.1 1.96 1.16 0.93 0.46 
3.  S. aureus Test drug, 1 g/200 g 2.6 2.6 2.1 2 1.3 1 0.7 
2.6 2.5 2.1 1.8 1.1 1.1 0.3 
2.7 2.4 2 1.8 1.3 1 0.6 
Average: 2.63 2.5 2.07 1.87 1.23 1.03 0.53 
4.  E. coli Test drug 
1 g/200 g 
2.4 2.2 2 1.9 1.4 1 0.6 
2.4 2.4 2.2 2.1 1.2 1 0.6 
2.3 2.3 2.1 2 0.9 0.8 0.3 
Average: 2.37 2.3 4.9 2.0 1.17 0.93 0.5 
5.  S. aureus Levomekol, 0.2 g/200 
g 
2.8 2.6 2.4 2.0 1.4 1.1 0.9 
2.8 2.6 2.3 2.2 1.2 1.0 0.8 
2.3 2.2 2.1 2.0 1.3 1.1 0.7 
Average: 2.63 2.5 2.27 2.07 1.3 1.07 0.8 
6.  E. coli Levomekol, 0.2 g/200 
g 
2.5 2.3 2.3 2.0 1.6 1.2 1.0 
2.5 2.5 2.4 2.2 1.5 1.1 0.7 
2.6 2.5 2.4 2.2 1.4 1.1 0.6 
Average: 2.53 2.43 5.57 2.13 1.5 1.13 0.77 
7.  S. aureus Levomekol, 1 g/200 g 2.7 2.5 2.2 2.0 1.3 1.1 0.8 
2.6 2.6 2.4 2.1 1.3 1.1 0.7 
2.8 2.3 2.2 2.1 1.3 1.0 0.8 
Average: 2.7 2.46 2.27 2.07 1.3 1.07 0.76 
8.  E. coli Levomekol, 1 g/200 g 2.5 2.3 2.3 2.0 1.4 1.1 0.9 
2.6 2.4 2.4 2.1 1.5 1.1 0.8 
2.6 2.4 2.4 2.1 1.5 1.1 0.6 
Average: 2.57 2.36 2.36 2.07 1.47 1.1 0.8 
9.  S. aureus Without drugs 2.5 2.5 2.3 2.0 1.8 1.2 1.1 
2.6 2.5 2.4 2.3 2.0 1.6 1.2 
2.6 2.6 2.5 2.4 1.5 1.3 1.0 
Average: 2.57 2.53 2.4 2.23 1.77 1.37 1.1 
10.  E. coli Without drugs 2.6 2.5 2.5 2.2 1.8 1.6 1.2 
2.6 2.6 2.4 2.3 2 1.5 1 
2.7 2.8 2.5 2.3 1.7 1.5 1.1 
Average: 2.63 2.63 2.47 2.27 1.83 1.53 1.1 
11.  Without 
infection 
Test drug, 0.2 g/200 g 2.4 2.4 2.2 2.0 1.3 1.2 0.8 
2.7 2.6 2.2 2.0 1.0 0.9 0.6 
2.8 2.7 2.4 1.8 1.2 1.0 0.7 
Average: 2.6 2.57 2.27 1.93 1.17 1.03 0.7 
12.  Test drug, 1 g/200 g 2.5 2.5 2.3 2.0 1.3 1.1 0.8 
2.7 2.6 2.3 2.0 1.3 1.0 0.7 
2.6 2.6 2.4 1.9 1.3 1.0 0.6 
Average: 2.6 2.57 2.33 1.97 1.3 1.03 0.6 
13.  Levomekol, 0.2 g/200 
g 
2.6 2.6 2.4 1.8 1.4 1.2 1.1 
2.8 2.7 2.6 2.0 1.3 1.1 0.7 
2.7 2.7 2.2 1.4 1.2 1.0 0.6 
Average: 2.7 2.67 2.4 1.73 1.3 1.1 0.8 
14.  Levomekol, 1 g/200 g 2.7 2.6 2.4 1.9 1.4 1.1 0.7 
2.7 2.6 2.4 1.9 1.4 1.1 0.9 
2.5 2.5 2.3 2.0 1.3 1.0 0.8 
Average: 2.63 2.57 2.37 1.87 1.7 1.07 0.7 
15.  Without drugs 2.8 2.7 2.4 2.0 1.4 1.2 1.0 
2.7 2.7 2.6 2.3 1.8 1.5 1.2 
2.8 2.8 2.6 1.6 1.4 1.2 0.7 
Average: 2.77 2.73 2.53 1.97 1.53 1.3 0.97 
 
Discussion 
 
Levomekol was used as a reference drug. In 
the international practice, it has been known since the 
70s as "Chloramphenicol + Methyluracil", and is a 
combined drug for local administration, having an anti-
inflammatory effect. It is also active against gram-
positive and gram-negative microbes (staphylococci, 
Pseudomonas bacilli and e-coli), penetrates tissues 
without damaging biological membranes and 
stimulates regeneration processes (Azuma, 2015; Dai, 
2011) [3], [4]. Levomekol is widely used in surgical 
practice for any type of tissue damage, mainly 
infected ones, with mixed microflora in the first purulo-
necrotic phase of the wound process (Brkich et al., 
2018; Shipovskaia, Zudina, Fomina, 2015) [5], [6]. 
The model of septic wounds in rats as per the 
P.I. Tolstykh method was used during the study of the 
specific activity of the drug with a comprehensive 
therapeutic effect based on derivatives of 
glucosamine and acrylic polymers for the treatment of 
infected wounds (Tolstykh et al., 2013) [2]. The 
infection was performed with the S. aureus and E. coli 
strains. The study lasted 18 days, and during this 
period no full scarring occurred. The wound diameter 
was chosen as the effectiveness criterion. 
 
Figure 2: The wound healing dynamics in the Test Drug group in 
the case of S. Aureus infection 
 
The bacterially infected wounds healed worse 
than the uninfected ones. On the 18th day of the 
study, the average diameter of the wounds infected 
with S. aureus (group 9) or E. coli. (group 10) was 1.1 
cm, and in group 15 – 0.97 cm.  
The healing rate of an uninfected and 
untreated wound was 0.1 cm/day (Table 2). The 
average diameter of the wounds without infection to 
which the preparations were applied on the first day of 
the study was 2.66 cm (groups 11 – 15). The rate of 
wound healing without infection after the application of 
the test drug was 0.105 cm/day for a dose of 0.2 
g/200 g (group 11), and 0.111 for a dose of 1 g/200 g 
(group 12). The rate of wound healing with the 
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application of Levomekol was 0.105 cm/day for a dose 
of 0.2 g/200 g (group 13), and 0.107 cm/day for a 
dose of 0.2 g/200 g (group 14). The rate of healing of 
the uninfected wounds when applying a larger amount 
of the test or the reference drug was slightly higher. In 
general, the rate of healing of the uninfected wounds 
when applying the test drug was 1.11 times greater 
than the healing of the uninfected untreated wounds, 
and 1.07 times greater for the reference drug. 
The size of the wounds on day 1 of the study 
after the infection with S. aureus in five groups of 
animals (1, 3, 5, 7, 9) averaged 2.63 cm. The 
dynamics of healing are presented in Figure 2. 
The size of the wound on the 18th day of the 
study without the use of drugs was 1.1 cm. On the 
18th day of the experiment, after applying the test 
drug to the wounds, the wound diameter decreased to 
0.5 cm (dose of 0.2 g/200 g of the live weight) and 0.6 
cm (dose of 1 g/200 g of the live weight). The wound 
healing rate was 0.117 cm/day for groups 1 and 3, 
which suggests that increasing the drug dose by more 
than 0.2 g per 200 g of the live weight lacked greater 
healing effect on wounds infected with S. aureus. For 
group 9 (healing with infection, without applying gels), 
the wound healing rate was 0.082 cm/day. The use of 
the studied gel increases the wound healing rate 1.43 
times compared to the group of animals with the 
infected wounds, on which the gel was not applied. 
The size of the wounds on day 1 of the study 
after the infection with E. coli in five groups of animals 
(2, 4, 6, 8, 10) averaged 2.63 cm. The dynamics of 
healing are presented in Figure 3. 
 
Figure 3: The wound healing dynamics in the Test Drug group in 
the case of E. coli infection 
 
The size of the wound on the 18th day of the 
study without the use of drugs was 1.1 cm, as in case 
of infection with E. coli (healing rate – 0.077 cm/day). 
On the 18th day of the experiment, after applying the 
test drug to the wounds, the wound diameter 
decreased to 0.46 cm (dose of 0.2 g/200 g of the live 
weight) and 0.5 cm (dose of 1 g/200 g of the live 
weight). The wound healing rate was 0.105 cm/day for 
group 2 and 0.104 for group 4, which suggests that 
increasing the drug dose by more than 0.2 g per 200 g 
of the live weight lacked greater healing effect on the 
wounds infected with E. coli. The use of the studied 
gel increases the wound healing rate 1.36 times 
compared to the group of animals with the infected 
wounds, on which the gel was not applied. 
After applying the Levomekol reference test 
drug to the wounds infected with S. aureus, on the 
18th day of the experiment, the wound diameter 
decreased to 0.8 cm (dose of 0.2 g/200 g of the live 
weight) and 0.76 cm (dose of 1 g/200 g of the live 
weight). The data are presented in Figure 4. 
 
Figure 4: The wound healing rate in S. aureus infection 
 
The wound healing rate was 0.102 cm/day for 
group 5 and 0.104 for group 7, which suggests that 
increasing the drug dose by more than 0.2 g per 200 g 
of the live weight lacked greater healing effect on the 
wounds. The use of Levomekol increases the healing 
rate of the wounds infected with S. aureus 1.27 times 
compared to the group of animals with the infected 
wounds to which the gel was not applied. 
 
Figure 5: The wound healing rate in E. coli infection 
 
In case of the wound infection with S. aureus, 
the healing rate in the group with the test drug was 
higher than in the group with the reference Levomekol 
drug by 1.2 mm/day in diameter. The wound healing 
rate in the group with the test drug was statistically 
significantly higher than that in the group of animals 
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with the infected and untreated wounds (group 9). 
After applying the Levomekol reference test 
drug to the wounds infected with S. aureus, on the 
18th day of the experiment, the wound diameter 
decreased to 0.8 cm (dose of 0.2 g/200 g of the live 
weight) and 0.76 cm (dose of 1 g/200 g of the live 
weight.). The data are presented in Figure 5. 
The wound healing rate for groups 6 and 8 
was 0.098 cm/day. The use of Levomekol increased 
the healing rate of the wounds infected with E. coli 
1.27 times, as well as of the wounds infected with S. 
aureus, compared to the group of animals with the 
infected wounds, on which the gel was not applied, 
indicating the same effectiveness of Levomekol on 
this model of septic wounds. 
In case of the wound infection with E. coli, the 
healing rate in the group with the test drug was higher 
than that in the group with the reference Levomekol 
drug by 1.2 mm/day in diameter. The wound healing 
rate in the group with the test drug was statistically 
significantly higher than that in the group of animals 
with the infected and untreated wounds (group 10). 
 
 
Discussion 
 
The obtained data prove the specific action of 
the drug with a comprehensive therapeutic effect 
based on derivatives of glucosamine and acrylic 
polymers to treat the infected wounds of various 
origins. The study has shown that the bacterially 
infected wounds healed worse than the noninfected 
ones. Both types of wounds — infected and 
uninfected ones — healed faster when applying the 
test drug or Levomekol ointment. When infected with 
S. aureus and E. coli, the studied drug showed the 
best result in wound healing compared with 
Levomekol. Increasing the dose of drugs more than 
0.2 g per 200 g of the live weight lacked greater 
healing effect both in S. aureus and in E. coli infection. 
On a model of a planar infected wound, the 
developed drug with comprehensive therapeutic effect 
has shown better wound healing effect compared with 
the Levomekol reference drug.  
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